# A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors

> **NCT01626209** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology

## Interventions

- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01626209
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01626209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01626209, "A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01626209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*